NATIONAL INSTITUTES OF HEALTH
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Phase 2
Terminated
- Conditions
- Leukemia, Adult T-Cell
- Interventions
- Biological: Denileukin diftitox (Ontak)
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00117845
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
Phase 1
Completed
- Conditions
- Neoplasms
- First Posted Date
- 2005-07-01
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT00117013
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Raloxifene in Preventing Breast Cancer in Premenopausal Women
Phase 2
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2005-06-23
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019500
- Locations
- πΊπΈ
Medicine Branch, Bethesda, Maryland, United States
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Phase 2
Completed
- Conditions
- Lymphoma, Mantle CellMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2005-06-17
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT00114738
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Phase 2
Completed
- Conditions
- Recurrent Squamous Cell Carcinoma of the LarynxRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Verrucous Carcinoma of the Oral CavitySalivary Gland Squamous Cell CarcinomaStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the NasopharynxStage IVA Salivary Gland Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00114283
- Locations
- πΊπΈ
University of Virginia, Charlottesville, Virginia, United States
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
Phase 2
Completed
- Conditions
- Stage IV Pancreatic Cancer
- Interventions
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00114244
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 2
Completed
- Conditions
- Adenocarcinoma of the PancreasStage III Pancreatic CancerStage II Pancreatic Cancer
- Interventions
- Radiation: radiation therapyBiological: bevacizumabProcedure: therapeutic conventional surgery
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 82
- Registration Number
- NCT00114179
- Locations
- πΊπΈ
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
Phase 1
Completed
- Conditions
- Chronic Myeloproliferative DisordersLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
- Interventions
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00114257
- Locations
- πΊπΈ
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
Phase 3
Active, not recruiting
- Conditions
- DS Stage I Multiple MyelomaSmoldering Multiple MyelomaDS Stage II Multiple MyelomaDS Stage III Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationOther: Laboratory Biomarker AnalysisProcedure: Peripheral Blood Stem Cell TransplantationOther: Placebo Administration
- First Posted Date
- 2005-06-14
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 460
- Registration Number
- NCT00114101
- Locations
- πΊπΈ
Mayo Clinic in Florida, Jacksonville, Florida, United States
πΊπΈOSF Saint Francis Medical Center, Peoria, Illinois, United States
πΊπΈIllinois Valley Hospital, Peru, Illinois, United States
Vaccine and Antibody Treatment of Prostate Cancer
Phase 1
Completed
- Conditions
- Prostatic Neoplasms
- First Posted Date
- 2005-06-13
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00113984
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States